A study has reported that combined radiomics signatures and clinical risk factors such as carcinoembryonic antigen (CEA) are valuable to evaluate the lymph node metastasis in CRC patients (19). The gene discussed is CEACAM5; the disease is metastatic malignant neoplasm in the lymph nodes.